Chris Viehbacher’s six-year tenure as Sanofi’s transforming chief executive ended suddenly Oct. 29 when the French drug maker’s board of directors voted unanimously at a morning meeting to remove him from the role, forcing his resignation.
Viehbacher, a citizen of Canada and Germany who previously worked at GlaxoSmithKline PLC, had, according to media reports, clashed with the board over planned job cuts that had angered the French government, disappointing earnings last year and Viehbacher’s decision this year to move to
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?